Camurus (CAMX) Company presentation summary

Strategy and 2027 outlook

• Priorities: grow Buvidal and Brixadi, expand markets, advance R&D, pursue business development, and sustain operational excellence.

• Vision 2027 targets five-fold revenue growth to SEK 4.5bn, US commercial infrastructure, approvals for four pipeline programs, and ~50% operating margin.

• Snapshot: 275+ employees, listed on Nasdaq Stockholm under ticker CAMX, with sustainable profitability since 2022.

Financial position and guidance

• FY 2025 revenue guidance is SEK 2.7–3.0bn, up 45–61% vs. 2024; profit before tax guidance is SEK 0.9–1.2bn, up 63–117%.

• Cash position ~SEK 3.3bn with no debt; planned investment includes R&D and US commercial infrastructure.

Opioid dependence products

• Buvidal and Brixadi provide weekly and monthly long-acting buprenorphine treatment; access spans four continents.

• Estimated 65,000 patients were treated with Buvidal in Europe and Australia at end-June 2025; sales CAGR was 87% since first launch in 2019, with a target of >100,000 patients in 2027.

• Three new Buvidal markets were being introduced in 2025—Switzerland, Luxembourg and Portugal—with four market authorization applications under review.

• Brixadi royalty grew 32% QoQ at constant exchange rates in Q2 2025; estimated US long-acting injectable buprenorphine share was ~25%, with peak market potential estimated at >$1bn.